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Abstract
 
Although it is clear that the function of CD40 on peripheral hematopoietic cells is pivotal to the
development of autoimmunity, the function of CD40 in autoimmune disease outside this com-
partment is unresolved. In a model of experimental autoimmune encephalomyelitis (EAE), evi-
dence is presented that CD40–CD154 interactions within the central nervous system (CNS) are
critical determinants of disease development and progression. Using bone marrow (BM) chi-
meric mice, the data suggest that the lack of expression of CD40 by CNS-resident cells dimin-
ishes the intensity and duration of myelin oligodendrocyte glycoprotein (MOG)-induced EAE
and also reduces the degree of inflammatory cell infiltrates into the CNS. Although CNS inflam-
 
mation is compromised in the CD40
 
1
 
/
 
1
 
®
 
CD40
 
2
 
/
 
2 
 
BM chimeric mice, the restricted CD40
expression had no impact on peripheral T cell priming or recall responses. Analysis of RNA ex-
pression levels within the CNS demonstrated that encephalitogenic T cells, which entered a
CNS environment in which CD40 was absent from parenchymal microglia, could not elicit the
expression of chemokines within the CNS. These data provide evidence that CD40 functions
outside of the systemic immune compartment to amplify organ-specific autoimmunity.
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Introduction
 
It is now well established that the development of inflamma-
tory diseases is dependent on interactions of CD40 with its
ligand, CD154 (for reviews, see references 1 and 2). Numer-
ous models of T cell–mediated autoimmunity in mice have
been shown to be completely prevented by prophylactic
blockade or by genetic deletion of this ligand–receptor pair
(3–8). It is now known that CD40 blockade impairs the
priming of T cells and prevents the differentiation of inflam-
matory T cells. This effect is due to the impairment of den-
dritic cell maturation and the lack of IL-12 production in
the absence of CD154 function (8). The capacity of anti-
CD154 mAbs to completely block the development of a
 
central nervous system (CNS)
 
1
 
-targeted autoimmune dis-
ease, experimental autoimmune encephalomyelitis (EAE), is
likely due to the reduced frequency of inflammatory, en-
cephalitogenic T cells induced in the absence of CD154
function (5, 7, 9). Although these observations explain why
CD154–CD40 interactions are critical for the development
of EAE, they do not answer why CD154 function is critical
even after the priming, expansion, and differentiation of au-
toaggressive T cells. That is, in several T cell–mediated au-
toimmune models (10), including EAE, anti-CD154 treat-
ment of mice with established disease ameliorates disease or
prevents relapse formation (7). Although the mechanism(s)
of this protection is poorly understood, CD40-bearing cells
at the site of inflammation may play a critical role in the pro-
gression of autoimmunity.
There are several CD40-bearing cell types within the
CNS that have demonstrated the capacity to be immuno-
regulatory and therefore may play an important role in the
pathogenesis of inflammatory processes within the brain
(11). For example, CD40-bearing macrophages located in
the perivascular and meningial space may play a critical role
in triggering autoreactive T cells to extravasate the blood–
brain barrier, penetrate the parenchyma, and facilitate in-
flammation (12). In addition to perivascular cells, CNS-res-
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ident parenchymal cells have been shown to present anti-
gen in vitro
 
 
 
and express an array of molecules allowing
them to potentially interact with T cells (13–15). CD40
expressed by parenchymal microglial cells has been impli-
cated in playing a proinflammatory function, because its
engagement triggers the release of IL-12 and thus could fa-
cilitate the generation of inflammatory T cells within the
CNS (16–18). Although much circumstantial evidence ex-
ists as to the immunoregulatory function of CNS-resident
cells in EAE, little or no in vivo data supporting their con-
tribution to inflammation has been reported. This report
provides in vivo data showing that CD40 expression by
cells outside the systemic immune compartment function-
ally contributes to the progression of EAE.
The use of bone marrow (BM) chimeric mice has al-
lowed studies to selectively manipulate the genotype of the
peripheral hematopoietic immune system from that of the
CNS resident cells, as CNS parenchymal microglia are not
repopulated after BM reconstitution (19, 20). In contrast to
the CNS parenchyma, the genotype of the systemic im-
mune compartment and that of perivascular cells can be ex-
changed with that of donor-derived hematopoietic cells
(20, 21). Using these approaches, several significant studies
have provided valuable insights into the function of CNS-
resident cells in the pathogenesis of EAE (12, 19, 22).
In this study, we provide in vivo
 
 
 
evidence showing that
CD40 expressed by CNS-endogenous cells controls the
migration and retention of myelin oligodendrocyte glyco-
protein (MOG)-reactive T cells in the CNS of mice during
EAE. We show that in the absence of CD40 expression
within the CNS, encephalitogenic T cells cannot manifest
inflammatory responses even though they themselves ap-
pear to be fully differentiated inflammatory T cells.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 and CD45 congenic C57BL/6-
Ly5.2 mice were obtained from National Cancer Institute (Fred-
erick, MD). CD40
 
2
 
/
 
2
 
 C57BL/6 mice were originally purchased
from The Jackson Laboratory and bred in house under pathogen-
free conditions.
 
Irradiation BM Chimeric Mice.
 
BM donor mice were killed
using CO
 
2
 
 and BM cells were isolated by flushing femur and
tibia bones with balanced salt solution (BSS). BM was filtered
through a 100-
 
m
 
m cell strainer and cells were washed with BSS.
CD45 congenic recipient mice were lethally irradiated with
1,200 rads (split dose) and intravenously injected with 20 
 
3
 
 10
 
6
 
BM cells. Engraftment took place over 6–8 wk of recovery.
Mice were bled retroorbitally to ensure 
 
.
 
95% engraftment of
blood leukocytes.
 
Peptides and Abs.
 
MOG
 
35–55
 
 peptide (MEVGWYRSPFSRV-
VHLYRNGK) was obtained from Research Genetics. For cyto-
fluorometric analysis, the following Abs were used: anti-CD45,
CD45.1, CD45.2, CD11b (Mac1), CD4, CD62L, CD44,
CD45RB, B7.1, B7.2, and MHC II. All Abs were obtained from
BD PharMingen. For in vivo administration, anti-CD154 (MR-
1; reference 23) was used at 350 
 
m
 
g/ml. As a control, hamster
(H)-Ig was used at the same concentration. Mice were injected
three times per week intraperitoneally.
 
Induction of EAE.
 
For active immunization, 5–8-wk-old fe-
male C57BL/6 or CD40
 
2
 
/
 
2
 
 mice (13–16-wk-old BM chimeric
mice) were immunized subcutaneously with 200 
 
m
 
g of MOG
 
35–55
 
peptide emulsified in CFA supplemented with 500 
 
m
 
g of 
 
Myco-
bacterium tuberculosis
 
 (DIFCO). The mice received intraperitoneal
injections with 250 ng pertussis toxin (Sigma-Aldrich) at the time
of immunization and 48 h later. After 7 d, the mice received an
identical boost immunization with MOG/CFA without pertussis
toxin. Clinical disease usually commences between day 13 and 18
after immunization.
For adoptive transfer, donor mice were immunized subcutane-
ously with 200 
 
m
 
g MOG
 
35–55
 
 in CFA supplemented with 500 
 
m
 
g
 
Mycobacterium tuberculosis
 
. Immediately after and 2 d later the mice
received 250 ng of pertussis toxin. 11 d after immunization, the
mice were killed and spleens were removed, homogenized, and
RBCs were lysed. The cells were cultured for 4 d in RPMI 1640
supplemented with 10% FCS (both obtained from BioWhitaker),
10 
 
m
 
g/ml of MOG peptide, and 2.5 ng/ml of recombinant IL-12
(PeproTech). The cells were harvested, and dead cells were re-
moved by Ficoll (Sigma-Aldrich) centrifugation. Cells are then
washed and injected into recipient mice (5–25 
 
3 
 
10
 
6
 
 cells/
mouse). Animals received 250 ng/mouse pertussis toxin on day 0
and 2 after transfer. Clinical disease usually begins 6–10 d after
cell transfer.
 
Clinical Evaluation.
 
The mice were scored four times per
week as follows: 0, no detectable signs of EAE; 0.5, distal limp
tail; 1, complete limp tail; 1.5, limp tail and hind limb weakness;
2, unilateral partial hind limb paralysis; 2.5, bilateral partial hind
limb paralysis; 3, complete bilateral hind limb paralysis; 3.5, com-
plete hind limb paralysis and unilateral forelimb paralysis; 4, total
paralysis of fore and hindlimbs (score 
 
.
 
4 to be killed); 5, death.
 
Histology.
 
Mice were killed with CO
 
2
 
. Spinal column was
removed and fixed in 10% buffered formalin. The spinal cord was
dissected and paraffin embedded before staining with either he-
matoxylin and eosin to assess infiltration or luxol fast blue to as-
sess the degree of demyelination.
 
Flow Cytometry.
 
Mice were killed with CO
 
2
 
 and spinal cords
were removed by flushing the spinal column with sterile BSS.
The brain was dissected to isolate the brain stem. Both tissues
were homogenized and strained through a 100-
 
m
 
m nylon filter
(Fisher Scientific). After centrifugation, the cell suspension was
resuspended in 37% isotonic Percoll and underlayed with 70%
isotonic Percoll. The gradient was centrifuged at 600 
 
g
 
 for 25 min
at room temperature. The interphase cells were collected and ex-
tensively washed before staining. For flow cytometry, the cells
were stained with primary Abs for 30 min at 4
 
8
 
C, washed, and
incubated with streptavidin-allophycocyanin (APC) or peridinine
chlorophyll protein (PerCP; BD PharMingen) for 15 min. The
cells were washed and analyzed using a FACSCalibur™ using
CELLQuest™ software (Becton Dickinson). Postacquisition
analysis was performed using WinMDI 2.8 software (Scripps-
Research Institute).
 
Recall Responses.
 
Mice were primed by flank injections of
MOG/CFA. After 5 d, the axillary and inguinal LNs were re-
moved and homogenized. 5 
 
3 
 
10
 
5
 
 LN cells were placed as tripli-
cates in a 96-well plate and pulsed with different amounts of
MOG peptide or irrelevant peptide (myelin proteolipid protein
[PLP
 
139–151
 
]; Research Genetics) as a control. After 48 h, cells
were pulsed with [
 
3
 
H]thymidine (NEN Life Science Products/
Dupont) and incubated for an additional 15 h before cells were
harvested and thymidine incorporation was assessed using a Fil-
termate harvester (Packard Instrument Co.) and TopCount-
NXT Microplate scintillation and luminescence counter (Packard 
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Instrument Co.). For cytokine analysis, sister cultures were har-
vested 48 h after culture supernatants were analyzed by ELISA for
IFN-
 
g
 
 and IL-4 (BD PharMingen).
 
RNase Protection Assays.
 
Mice were killed with CO
 
2
 
 and spi-
nal cords were removed by flushing with sterile BSS. Total RNA
was isolated using TRIzol reagent (Life Technologies) following
the manufacturer’s recommendations. Chemokine mRNA levels
were determined using the Riboquant Multiprobe RNase Pro-
tection Assay system (BD PharMingen). 
 
32
 
P-labeled riboprobes
were synthesized from a customized plasmid template set using
T7 polymerase. The DNA template was digested with DNase
and total RNA (15 
 
m
 
g) was hybridized with the riboprobes over-
night at 56
 
8
 
C. ssRNA species were removed by digestion with
RNase A. The protected RNA species were phenol/chloroform
extracted, ethanol precipitated, and electrophoresed on a 5%
polyacrylamide gel. Protected chemokine probes were visualized
by autoradiography of the dried gel.
 
Statistical Analysis.
 
Statistical differences of clinical diseases
scores were evaluated using a nonpaired Student’s 
 
t 
 
test. ELISA
and proliferation assays are expressed as average of triplicate
wells 
 
6 
 
SD. Significance was determined by single-factor analysis
of variance (ANOVA) and Bonferroni posttest. Differences were
considered significant when 
 
P 
 
value 
 
, 
 
0.05.
 
Results and Discussion
 
CD40–CD154 Function Is Essential for the Development of
EAE in Response to MOG Peptide.
 
Data presented in Fig.
1 establish that CD40–CD154 interactions are essential for
the development of MOG-induced EAE in C57BL/6 mice.
These data are consistent with EAE models in both SJL and
B10.PL mouse strains to other CNS peptides (7). Treatment
of mice with anti-CD154 mAb at the time of immunization
completely prevents clinical EAE (Fig. 1 A). Consistent
with the function of this ligand receptor pair in the devel-
opment of EAE are data establishing that CD40
 
2
 
/
 
2
 
 mice are
resistant to the induction of EAE via active immunization
(Fig. 1 B). In this experiment, one of the nine CD40
 
2
 
/
 
2
 
mice developed a limp tail. Treatment of mice with estab-
lished disease (day 13) causes a significant alleviation of clin-
ical symptoms over time, compared with control mice (Fig.
1 C), indicating that even after the encephalitogenic T cells
infiltrate the CNS, anti-CD154 can interfere with the effec-
tor phase of the disease.
To determine whether encephalitogenic T cells were
generated, CD40
 
2
 
/
 
2
 
 as well as CD40
 
1
 
/
 
1
 
 mice were im-
Figure 1. CD40 is critical for the induction of active MOG-EAE in C57BL/6 mice and T cell priming. (A) Early administration of anti-CD154 blocks
the development of MOG-induced EAE. Mice were immunized with MOG35–55 in CFA and given 350 mg/mouse of anti-CD154 mAbs three times per
week starting at the time of immunization (n). Control mice were treated with H-Ig mAbs (r; n 5 6/group). (B) CD402/2 mice are not susceptible to
MOG-induced EAE. CD402/2 (h) and CD401/1 (r) mice were immunized as described in panel A, and disease was monitored (n 5 9/group). (C)
Treatment of mice with anti-CD154 at disease onset ameliorated MOG-induced EAE. Mice were treated at the first sign of clinical disease with either
anti-CD154 (n) or control H-Ig (r) (n 5 9/group). (D) T cell priming to MOG is reduced in CD402/2 mice. To assess the ability of CD402/2 mice
to prime T cells against MOG35–55, CD401/1 (1/1) or CD402/2 (2/2) mice were immunized with MOG35–55 in CFA. LN cells were harvested after
5 d and stimulated with either no antigen, 100 mg of MOG35–55, or irrelevant PLP peptide. (E) MOG-induced IFN-g secretion is reduced in CD402/2
mice. IFN-g production from LN cells primed to MOG35–55 in CD401/1 and CD402/2 was assessed in vitro as described in D. Displayed is a represen-
tative of at least three experiments. 
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munized with MOG35–55 in CFA, and 5 d later LN cells
were isolated. LN cells were cultured in the presence or
absence of irradiated syngeneic splenocytes with either
MOG peptide or irrelevant PLP peptide. Fig. 1, D and E,
shows by recall assay that priming of naive T cells to MOG
peptide is drastically reduced in CD402/2 animals. Even
though low level antigen-induced proliferative activity was
measured in T cells from CD402/2 mice (Fig. 1 D), IFN-g
secretion by these T cells is completely blocked (Fig. 1 E).
Although IFN-g production was blocked, no IL-4 was de-
tected upon recall, indicating that there is no overt emer-
gence of Th2-like cells in the absence of CD40 (not
shown).
Fig. 2 shows that neither CD402/2 (Fig. 2 C) nor anti-
CD154–treated mice (Fig. 2 D) show any sign of inflam-
mation of the CNS compared with mice treated with H-Ig
as established by histology (Fig. 2 B). On day 7 after dis-
ease onset, cells derived from spinal cord cell suspension
were separated over a discontinuous Percoll gradient and
stained with anti-CD45 and anti-CD11b mAbs. Cytofluo-
rometric analysis of the CNS-infiltrating cells shows that
infiltrating lymphocytes (CD11b2/CD45hi) and blood-
derived phagocytes (CD11b1/CD45hi) are absent in im-
munized CD402/2 mice (Fig. 2 E) compared with CD401/1
mice (Fig. 2 F). No significant changes were observed in
the number of resident microglial cells (CD11b1/CD45lo).
In summary, in the absence of CD40, naive MOG-specific
T cells are not sufficiently stimulated to become encepha-
litogenic and fail to penetrate the blood–brain barrier and
cause disease.
Analysis of the Induction of Actively Induced EAE in Mice
That Do Not Express CD40 within the CNS but Express
CD40 in the Peripheral Hematopoietic Compartment. In or-
der determine if CD40 expression within the CNS con-
tributes to the development and progression of EAE, BM
chimeric mice were produced in which CD40 expression
was limited to the radioresistant or radiosensitive compart-
ment of the host. Fig. 3, A–D, shows the staining of the
CNS of BM chimeric mice 2 mo after reconstitution with
CD45 (Ly5)-congenic BM. Although resident microglial
cells are hematopoietically derived, they do not turnover
after irradiation and BM reconstitution (20). Hence, the
CD45low/Mac11 CNS-resident microglia express the host
congenic CD45.2 marker (Fig. 3 A). After induction of
EAE, CNS-infiltrating CD45high cells predominantly ex-
pressed the donor CD45.1 marker, indicating that the host
Figure 2. CD40–CD154 blockade inhibits extravasation of leukocytes into the CNS. (A–D) Genetic deficiency of CD40 or anti-CD154 treatment re-
duces leukocyte infiltration into the CNS as assessed by histochemistry. EAE was induced in either CD401/1 or CD402/2 mice using MOG35–55 emul-
sified in CFA as described. CD401/1 mice were either treated with anti-CD154 or irrelevant H-Ig at the time of immunization (three times per week).
To quantify inflammatory infiltration into the CNS, 5–10 mice per group were killed 7 d after disease onset. Spinal cords and cerebella were collected
and either fixed in 10% formaldehyde/PBS or homogenized. Spinal cords from: (A) CD401/1 mice, nonimmune; (B) CD401/1 mice, immune and
treated with H-Ig; (C) CD402/2 mice, immune; and (D) CD401/1 mice, immune and treated with anti-CD154 at the time of immunization, were sec-
tioned and stained with hematoxylin and eosin. Displayed is a representative of at least three individual experiments. (E and F) Infiltration of leukocyte
subsets into the CNS is reduced in CD402/2 mice. Cells derived from spinal cord cell suspension were separated over a discontinuous Percoll gradient
and stained with anti-CD45 and anti-CD11b mAbs. Cells were analyzed by flow cytometry; (E) CD401/1 mice; (F) CD402/2 mice.971 Becher et al.
immune system is replaced by donor BM cells (Fig. 3 D).
Only a minor population of CNS infiltrating lymphocytes
are radioresistant and of host origin (Fig. 3 C). The extent
of peripheral hematopoietic chimerism was confirmed
through the analysis of the PBMCs, spleen, and LN. Al-
though small numbers of host-derived cells are found in the
blood (2%) and LNs/spleen (5%), the host-derived cells
consisted entirely of CD31 T cells. Neither myeloid cells
nor B lymphocytes (CD40-expressing cells) were found to
be of host origin (,0.1%) as assessed by B220 (B cells),
CD11b (monocytes/macrophages), and GR-1 staining
(granulocytes; data not shown).
Systemic and CNS-restricted immune responses were
evaluated in CD40 BM chimeric mice. Data presented in
Fig. 3, E and F, show that CD401/1®CD402/2 mice and
CD401/1®CD401/1 mice had comparable systemic (pe-
ripheral) immune responses. Chimeric mice were immu-
nized with MOG35–55 in CFA, and LN cells were isolated
5 d after immunization for the assessment of MOG recall
responses in vitro. CD402/2®CD401/1 and CD402/2®
CD402/2 mice do not generate strong T cell responses to
MOG as assessed by proliferation (Fig. 3 E) and IFN-g
production (Fig. 3 F). In contrast, both CD401/1®
CD402/2 and CD401/1®CD401/1  mice demonstrated
equivalent capacities to prime T cells and for those T cells
to proliferate and secrete IFN-g when rechallenged with
MOG in vitro. Thus, CD40 expression by the peripheral
hematopoietic cells is essential for priming of encephalito-
genic T cells. However, the lack of CD40 expression on
nonhematopoietic cells in the CD401/1®CD402/2 chi-
meras (endothelial cells, epithelial cells, etc.) appears to
have little or no impact on the priming and early differenti-
Figure 3. Analysis of the induction of actively induced EAE in irradiated BM chimeric mice. (A–D) In BM chimeric mice, the parenchymal micro-
glial cells are host derived and the infiltrating leukocytes are predominantly donor derived. Mice were irradiated and reconstituted with CD45.1-con-
genic BM cells. Engraftment took place over 2 mo. CNS cells of nonimmune mice were stained with either the (A) host (CD45.2) or (B) donor-con-
genic CD45.1 marker. C and D show the degree of chimerism of CNS-infiltrating leukocytes in BM chimeric mice with EAE induced by
immunization with MOG35–55 in CFA. (E and F) The lack of CD40 expression on radioresistant cells in the host does not influence peripheral T cell
responses. After 2 mo of recovery, mice were immunized with MOG/CFA and LNs were removed 5 d later. Recall proliferation (E) and IFN-g secre-
tion (F) in response to either 100 mg MOG peptide or irrelevant PLP peptide was assessed in vitro. (G) The lack of CD40 in the CNS reduces EAE.
CD401/1®CD401/1, CD401/1®CD402/2, CD402/2®CD401/1, and CD402/2®CD402/2 mice were produced, allowed to recover for 2 mo,
then immunized with MOG35–55 in CFA as described above and scored for clinical disease (n 5 5/group; representative of four individual experiments).
The clinical score of CD401/1®CD401/1 vs. CD401/1®CD402/2 is statistically significantly different (P , 0.05). EAE was scored over 24 d. (H and
I) The lack of CD40 expression in the CNS reduces the extent of leukocyte infiltration. 7 d after disease onset, leukocyte infiltration into the CNS of
(H) CD401/1®CD401/1 and (I) CD401/1®CD402/2 mice was analyzed as described.972 The Role of CD40 within the Inflamed Central Nervous System
ation of antigen-reactive T cells in the periphery. Hence,
the per-ipheral T cell response depends solely on the geno-
type of the BM donor and the expression of CD40 on
nonhematopoietic, host-derived cells is not necessary for
the peripheral T cell response against MOG35–55.
In parallel to the measurement of systemic immune re-
sponses in chimeric mice, CNS-restricted immune re-
sponses were also measured (Fig. 3 G). Mice in which
CD40 is absent from the systemic immune compartment
(either CD402/2®CD402/2 or CD402/2®CD401/1) are
resistant to develop EAE upon active immunization. Thus,
CD40 expression by the peripheral immune system is es-
sential for the development of EAE; CD40 expression
solely by nonhematopoietic cells or radioresistant hemato-
poietic cells (mainly parenchymal microglia) is inadequate
to support the development of EAE.
To address the function of CD40 within the CNS, active
induction of EAE in CD401/1®CD401/1 and CD401/1
®CD402/2 chimeras was compared (Fig. 3 G). The lack
of CD40 expression within the CNS parenchyma (CD401/1
®CD402/2) causes a significant delay in disease onset and
decreased severity compared with chimeric mice that ex-
press CD40 on resident CNS cells (CD401/1®CD401/1).
Table I summarized the clinical development in chimeric
mice obtained from three individual experiments.
The data do not specifically address the role of perivascu-
lar CD40 expression, as mice in which CD40 is absent
from the systemic/perivascular compartment do not gener-
ate encephalitogenic cells as described above. However, the
absence of parenchymal CD40 expression, when CD40 is
restricted to the hematopoietic, systemic, and perivascular/
meningeal compartment, results in significantly reduced in-
filtration of leukocytes (Fig. 3, H and I) as well as dimin-
ished and delayed clinical disease.
The Role of Systemic and CNS-restricted CD40 Expression
in the Effector Phase of Disease. To more extensively evalu-
ate the function of CD40 in the effector phase of EAE,
CD402/2 mice and CD40 BM chimeric mice were used in
an adoptive transfer model of disease. In this case, a popula-
tion of activated encephalitogenic effector T cells is adop-
tively transferred into mice that do or do not express CD40
Table I. EAE in CD40 BM Chimeras
Mice Incidence
Mean day
of disease
onset*
Mean maximal
clinical score*
CD401/1®CD401/1 16/17 15.8 3.2
CD401/1®CD402/2 14/17 18.5 2.5
CD402/2®CD401/1 3/17 18.3 2.0
CD402/2®CD402/2 1/16 18.0 2.8
This table summarizes the results of three independent experiments
where EAE was induced by active immunization in BM chimeric
animals. The overall clinical score of CD401/1®CD401/1 vs.
CD401/1®CD402/2 mice is significantly higher (P , 0.001),
whereas CD402/2®CD401/1 and CD402/2®CD402/2 do not differ
significantly (P . 0.05) as assessed using Student’s t test.
*Only diseased mice were included in the calculation.
Figure 4. Encephalitogenic T
cells are less effective at inducing
EAE when transferred into a
CD40-deficient host. (A) Adop-
tive transfer of MOG-reactive
T cells into a CD402/2 host
compared with transfer into
CD401/1 host results in less dis-
ease. MOG-reactive cells (15 3
106) were adoptively transferred
into either CD401/1 ( n) or
CD402/2 (h) recipients and the
mice were scored for clinical dis-
ease (n 5 6/group). (B and C)
Adoptive transfer of MOG-reac-
tive T cells can less effectively
infiltrate the CNS in a CD402/2
host.  7 d after disease onset,
mice were killed and CNS infil-
trates into (B) CD401/1 and (C)
CD402/2 mice were analyzed as
described. (D) Adoptive transfer
of MOG-reactive T cells into
CD401/1®CD402/2 BM chi-
meras results in less disease com-
pared with CD401/1®CD401/1
mice. MOG-reactive cells (20 3
106) were adoptively transferred
into either CD401/1®CD401/1
(e) or CD401/1®CD402/2 (h) recipients and the mice were scored for clinical disease (n 5 6/group). (E and F) Adoptive transfer of MOG-reactive
T cells can less effectively infiltrate when CD40 is absent from the CNS. 7 d after disease onset, mice were killed and CNS infiltrates into (E)
CD401/1®CD401/1 and (F) CD401/1®CD402/2 were analyzed as described.973 Becher et al.
in specific compartments. Furthermore, adoptive transfer
bypasses the need for T cell priming in secondary lymphoid
tissues and in contrast to active immunization, the largest
depot of available Ag is the CNS itself. Upon passive trans-
fer of MOG-reactive lymphocytes, CD402/2 mice are sig-
nificantly less susceptible to EAE induction than CD401/1
controls (Fig. 4 A). Like CD402/2 mice, CD401/1
®CD402/2 chimeric mice are also less susceptible pas-
sively transferred EAE and display a diminished disease se-
verity and disease incidence (Fig. 4 D). Significantly fewer
inflammatory infiltrates can be recovered from the CNS of
CD402/2 (Fig. 4 C) mice or CD401/1®CD402/2 (Fig. 4
F) recipients compared with CD401/1 (Fig. 4 B) mice or
CD401/1®CD401/1 chimeric mice (Fig. 4 E), respec-
tively. The data indicate that CD40 engagement within the
CNS is critical for the infiltration/retention of encephalito-
genic cells into the CNS.
Although the CD40 genotype of the host influenced the
magnitude of the T cell infiltration, no phenotypic differ-
ences of the T cells were noted. In general, a two- to four-
fold difference in the total number of infiltrating cells were
noted between hosts that expressed CD40 in the CNS ver-
sus those that did not express CD40. No differences in the
phenotypic profile of CNS infiltrates between CD401/1
and CD402/2 recipients with regards to expression of
CD44, CD45RB, CD62L, and CD25 on CD41 T cells
were observed (not shown). Furthermore, upon rechallenge
with MOG peptide in vitro, CNS infiltrating cells collected
from the CNS of BM chimeric mice revealed that they are
able to secrete IFN-g regardless of whether they infiltrate a
CD401/1 or CD402/2 CNS (not shown).
Reduced T cell infiltration/recruitment and disease sug-
gested that the absence of CD40 in the CNS impeded the
production of critical inflammatory mediators within the
CNS needed to recruit encephalitogenic T cells and cause
disease. To address the validity of this hypothesis, mRNA
expression levels of several relevant chemokines in the
CNS of BM chimeric mice immunized with MOG35–55
peptide was quantitated. Fig. 5 A shows an RNase protec-
tion assay revealing that the expression of chemokines is
drastically reduced in BM chimeras that do not express
CD40 within the CNS upon active immunization. The
mice were killed 5 d after disease onset. Consistent with
delayed disease onset, only one of the CD401/1®CD402/2
mice displayed clinical symptoms, in contrast to four
mice in the CD401/1®CD401/1 group (n 5 6 each
group). At this early time point, striking differences with
regards to chemokine expression were observed. The data
suggest that the absence of CD40 on CNS-resident APCs
results in the reduction of chemokine expression leading to
a decreased level of leukocyte infiltration. To confirm that
CD40 is critical during the effector phase of EAE, we
adoptively transferred MOG-reactive T cells into either
CD401/1 or CD402/2 recipients (Fig. 5 B). RNase pro-
tection assays of spinal cords of these mice after disease on-
set confirms the lack of chemokine mRNA induction
when CD40 was absent from the CNS. Furthermore, the
data suggest that the exaggerated reduction in chemokine
expression is not simply due to the reduced number of T
cells, which are observed in the CD402/2 mice.
Taken together, CD40 expression by CNS-resident cells
(most likely parenchymal microglia) is important for the in-
filtration/retention of inflammatory leukocytes into the
CNS. Confirmation that CD40 function within the CNS
significantly contributes to the pathogenesis of EAE pro-
vides a reasonable explanation for the therapeutic activity
of anti-CD154 therapy. In the absence of CD40 function,
reduced T cell infiltration, reduced production of inflam-
matory cytokines and chemokines within the CNS, and
blockade of peripheral CD40 function may all contribute
to the therapeutic activities of anti-CD154. Studies in mu-
rine models of EAE have guided the application of human-
ized anti–human CD154 for the treatment of multiple scle-
rosis. Currently, anti-CD154 is in phase II clinical trials in
patients with multiple sclerosis, and studies in mice con-
tinue to refine and redefine the function of this ligand–
receptor pair in CNS inflammatory diseases.
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AI37075 and the Schram foundation. B. Becher holds a fellowship
from the National MS-Society.
Figure 5. Chemokine expression within the CNS of CD401/1,
CD402/2, and BM chimeric mice. (A) Chemokine expression is reduced
in BM chimeras where CD40 is absent in the CNS. EAE was induced in
BM chimeric mice by active immunization (1®1  5 CD401/1  ®
CD401/1;  1®2  5 CD401/1  ®  CD402/2;  2®1  5 CD402/2
®CD401/1; 2®2 5 CD402/2®CD402/2). 5 d after disease onset
the animals were killed and total RNA was isolated from spinal cords and
analyzed for chemokine expression by RNase protection assay. Either 10
or 20 mg of RNA was loaded onto the gel. (B) Chemokine expression is
reduced in CD402/2 mice upon passive transfer of MOG-reactive cells.
EAE was induced in either CD401/1 or CD402/2 mice by adoptive
transfer of either 12 3 106 or 5 3 106 MOG-reactive cells and RNase
protection assay was performed as described. Mip, macrophage inflamma-
tory protein; IP-10, IFN-g–inducible protein 10; MCP-1, monocyte
chemoattractant protein 1; TCA-3, T cell activation gene 3; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.974 The Role of CD40 within the Inflamed Central Nervous System
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